Nano‑X Imaging Ltd. (NASDAQ: NNOX) announced that it will present its Nanox.ARC digital tomosynthesis system live in Europe for the first time at the European Congress of Radiology (ECR) in Vienna, Austria, from March 4‑8, 2026.
The Nanox.ARC system offers a smaller footprint, simplified installation, and a lower radiation dose compared with traditional CT scanners. The company will also demonstrate its TAP2D cloud‑enabled image‑enhancement feature, which received FDA 510(k) clearance on February 3, 2026.
In addition to the core imaging platform, Nano‑X will showcase three CE‑marked AI solutions—HealthCCSng for cardiac imaging, HealthOST for bone health, and HealthFLD for liver assessment—while previewing two AI tools still under development for aortic valve calcification and body‑composition measurement.
CEO and Acting Chairman Erez Meltzer said the European debut “represents a significant milestone in our European market expansion” and added that the company’s AI capabilities “demonstrate the Nanox end‑to‑end solution that can deliver immediate practical value to opportunities for proactive care.”
The live showcase marks a key commercial milestone as Nano‑X expands beyond the United States and targets the growing preventive‑screening market in Europe. The company has set a goal of deploying 100 ARC systems worldwide, but it continues to face financial challenges, including negative operating margins, cash burn, and a low Piotroski F-Score that signal ongoing execution pressure.
The event underscores Nano‑X’s strategy of combining affordable, portable imaging hardware with AI‑driven analytics to broaden access to high‑quality diagnostics, positioning the company to compete with established imaging vendors while navigating a competitive landscape that includes both traditional CT manufacturers and emerging AI‑centric platforms.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.